Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus for more than 6 months~* HbA1c (glycosylated haemoglobin A1c) between 7.5 % and 10.0% at trial initiation (screening)~* BMI (Body Mass Index) less than 40 kg/m2~* Basal insulin treatment for at least 3 months (NPH once or twice daily, insulin glargine or detemir once daily)~* Treatment with one to 3 OADs~Exclusion Criteria:~* Known or suspected allergy to trial products or related products~* Women who are pregnant, are breast-feeding or intend to become pregnant within the next 48 weeks~* Previous participation in any trial including this for the last 6 months~* Use of more than 1 U/kg of basal insulin daily at trial initiation (screening)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced (Type: EXPERIMENTAL): Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
- Basic (Type: ACTIVE_COMPARATOR): Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).